Brighton Jones LLC’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Brighton Jones LLC’s Portfolio IMPL Stock Details IMPL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-14,145	Closed	-$6.08K	–	616
2023 Q3	$6.08K	Hold	14,145	–	–	﹤0.01%	544
2023 Q2	$18K	Hold	14,145	–	–	﹤0.01%	543
2023 Q1	$19.8K	Hold	14,145	–	–	﹤0.01%	515
2022 Q4	$53K	Hold	14,145	–	–	﹤0.01%	464
2022 Q3	$69K	Hold	14,145	–	–	﹤0.01%	449
2022 Q2	$132K	Sell	14,145 -70	-0.5%	-$511	0.01%	445
2022 Q1	$91K	Buy	14,215 +70	+0.5%	+$529	﹤0.01%	500
2021 Q4	$122K	Buy	+14,145	New	+$141K	0.01%	508

Other funds holding IMPL

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

DJSG

D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Brighton Jones LLC's IMPL Position: Q4 2023 in Review

Brighton Jones LLC sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q4 2023, closing a stake of 14,145 shares — an estimated $6.08K sold.

Brighton Jones LLC first reported a position in IMPL in Q4 2021 and held it in 8 quarters. The position peaked at $132K in Q2 2022. 2 funds tracked by Wall St. Rank hold IMPL as of Q4 2023.

Brighton Jones LLC reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Brighton Jones LLC sold 14,145 Impel Pharmaceuticals Inc. Common Stock shares in Q4 2023, an estimated $6.08K.
Brighton Jones LLC first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q4 2021 and held it in 8 quarters.
Brighton Jones LLC's Impel Pharmaceuticals Inc. Common Stock position peaked at $132K in Q2 2022.
2 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q4 2023.

Based on Brighton Jones LLC's 13F filing for Q4 2023, filed 5 Feb 2024.